StreetAlpha.app
Home › Stocks › OBIO

Orchestra BioMed Holdings, Inc. (OBIO)

Healthcare
$6.58
▼ −6.00%
LAST CLOSE · NOV 20

Orchestra BioMed develops medical device therapies for high blood pressure and artery disease, working with large device makers such as Medtronic. It last closed at $6.58 on Nov 20, down 6.00% on the day. For the quarter ended Sep 2026, OBIO reported EPS of -$0.30 on revenue of $91,000, with revenue down 89.4% from a year ago. Over the last 12 months OBIO insiders bought $6.5M of stock on the open market and sold $439K, according to SEC Form 4 filings.

AI Auto Pilots
Is OBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OBIO.

Key Stats

Last 12 months
Results
Revenue
$31.2M
+1007.4% vs a year ago
Net income
−$57.0M
−182.5% margin
EPS (diluted)
−$0.75
Free cash flow
−$64.2M
−205.7% margin
Valuation
Market cap
$517.9M
78.7M shares
P/E
–
No P/E while losing money
Price to sales
16.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.8M
At Sep 30
Debt
$21.2M
At Sep 30
Shares outstanding
78.7M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $3.5M$3.5MFY2022FY2023: $2.8M$2.8MFY2023FY2024: $2.6M$2.6MFY2024FY2025: $33.5M$33.5MFY2025

From OBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.30
Quarter ended Sep 2026
Year ago EPS
-$0.40
Same quarter last year
Revenue
$91,000
−89.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.43Dec '24Mar 2025: -$0.49Mar '25Jun 2025: -$0.50Jun '25Sep 2025: -$0.40Sep '25Dec 2025: $0.26Dec '25Mar 2026: -$0.33Mar '26Jun 2026: -$0.38Jun '26Sep 2026: -$0.30Sep '26Latest -$0.30
Revenue by quarter
Dec 2024: $253,000Dec '24Mar 2025: $868,000Mar '25Jun 2025: $836,000Jun '25Sep 2025: $861,000Sep '25Dec 2025: $30.9MDec '25Mar 2026: $110,000Mar '26Jun 2026: $88,000Jun '26Sep 2026: $91,000Sep '26Latest $91,000
StreetAlpha's call on OBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on OBIO: 0 upgrades, 0 downgrades, 0 initiations
B. Riley FinancialReiterated
Nov 21Buy 
B. Riley FinancialReiterated
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on OBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OBIO

Technical Analysis

OBIO · as of the Nov 20 close · updated each morning
Uptrend

The stock is 6% above its 20 day and 9% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 55). The nearest support is the Pivot S1 at $6.31, and the nearest resistance the Pivot at $6.74.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 8.0%/day
Key levels
$7.8352 week high+19.0%
$7.01Pivot R1+6.5%
$6.74Pivot+2.4%
$6.58Last close
$6.31Pivot S1−4.1%
$6.1920 day average−5.9%
$6.0150 day average−8.7%
$5.75Swing low (Sep 24)−12.6%
$5.25100 day average−20.2%
$4.71200 day average−28.4%
$3.4652 week low−47.4%
Indicators
RSI (14)54.88Middle of its rangeNeutral
MACD0.33Above its signal lineBullish
Stochastic70.2Middle of its rangeNeutral
ADX (14)21.1Weak trend
Williams %R-45.7Oversold below −80, overbought above −20Neutral
CCI (20)67.5Oversold below −100, overbought above 100Neutral
Rate of change+15.8%Change over 10 sessionsBullish
ATR (14)$0.53Typical daily range, 8.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for OBIO

What happened before

See how OBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OBIOHow many large options trades hit OBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲58 buying vs 28 selling
  • ▲Held by funds +4.5 pts
  • ▲Funds holding +16
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9377+20.8%
In funds' top 1010–
Held by funds39.7%35.2%+4.5 pts
New / increased26 / 3225 / 22+23.4%
Reduced / sold out18 / 1015 / 130.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$6.5M13 buys · 7 insiders
Sold$439K7 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
Cluster buy: 5 insiders bought $6.2M between Nov 9 and Nov 9.
2026-03 bought $43K2026-04 sold $1322026-05 bought $139K2026-06 bought $19K2026-06 sold $58K2026-07 sold $64K2026-08 bought $11K2026-08 sold $61K2026-09 bought $48K2026-09 sold $74K2026-10 sold $95K2026-11 bought $6.2M2026-11 sold $86KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9Rtw Investments, LP10% ownerBuy1,200,000$5.00$6.0M
Nov 9Andrew Lawrence TaylorCFOBuy1,000$5.00$5K
Nov 9David P HochmanSee RemarksBuy5,000$5.00$25K
Nov 9David PacittiDirectorBuy20,000$5.00$100K
Nov 9Eric S FainDirectorBuy20,000$5.00$100K
Nov 2Darren ShermanSee RemarksSale plan15,000$5.74$86K
Every insider buy and sale for OBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OBIO insider trades →

From SEC Form 4 filings by OBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OBIO is in one of them and how their past OBIO trades turned out.

OBIO in the AI portfolios
Loading…

OBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OBIO in an article yet. Here's the latest on the wider market.

OBIO in the news

About Orchestra BioMed Holdings

Orchestra BioMed is a biomedical company based in New Hope, Pennsylvania, that develops medical device therapies. Its main candidates are AVIM Therapy, a bioelectronic treatment for high blood pressure that can be added to cardiac pacemakers as a software update, and Virtue SAB, a drug and device balloon for treating narrowed arteries. The company works with large medical device makers, including Medtronic, to bring these technologies to patients. Both products are still in clinical study and have not yet been approved by regulators.

Headquarters
New Hope, PA